Alzheimer's & dementia (Amsterdam, Netherlands) · 2026
Longitudinal changes in DTI-ALPS and choroid plexus volume relative to CSF biomarkers during lecanemab treatment in mild cognitive impairment: A pilot study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takahashi Toshiya, Kimura Kaku, Takenaka Shingo, Ono Sayaka, Fukui Maya, Okada Yasushi, Asada Tomohiko, Niimi Kan, Ikeda Akio, Takahashi Ryosuke, Matsumoto Riki, Fukuyama Hidenao
Аннотация
BACKGROUND: Lecanemab improves cerebrospinal fluid (CSF) biomarkers, but whether magnetic resonance imaging (MRI) proxies of CSF-interstitial fluid (ISF) exchange improve is unknown.
METHODS: This was a single-center prospective pilot (n = 8). The ALPS index was derived from diffusion tensor image analysis along the perivascular space (DTI-ALPS), and intracranial volume (ICV)-normalized choroid plexus (ChP) volume was segmented with FreeSurfer Sequence Adaptive Multimodal SEGmentation (SAMSEG). Baseline changes were tested with Wilcoxon signed-rank tests with Benjamini-Hochberg false discovery rate (FDR) control within prespecified MRI, CSF, and cognition endpoint families.
RESULTS: CSF Aβ42 and Aβ42/40 increased and tau phosphorylated at threonine 181 (p-tau181) decreased at 6 and 12 months (all q < 0.05); cognition showed no FDR-significant change. The ALPS index showed a downward tendency (9-month q = 0.010), and ChP/ICV increased at 6-12 months (all q = 0.010).
DISCUSSION: The ALPS index and ChP volume may be insufficient as stand-alone surrogate endpoints over 12 months. These findings suggest exploring complementary strategies targeting CSF-ISF exchange and clearance pathways and warrant larger controlled longitudinal studies.
CLINICAL TRIAL REGISTRATION INFORMATION: Not applicable (observational study).
METHODS: This was a single-center prospective pilot (n = 8). The ALPS index was derived from diffusion tensor image analysis along the perivascular space (DTI-ALPS), and intracranial volume (ICV)-normalized choroid plexus (ChP) volume was segmented with FreeSurfer Sequence Adaptive Multimodal SEGmentation (SAMSEG). Baseline changes were tested with Wilcoxon signed-rank tests with Benjamini-Hochberg false discovery rate (FDR) control within prespecified MRI, CSF, and cognition endpoint families.
RESULTS: CSF Aβ42 and Aβ42/40 increased and tau phosphorylated at threonine 181 (p-tau181) decreased at 6 and 12 months (all q < 0.05); cognition showed no FDR-significant change. The ALPS index showed a downward tendency (9-month q = 0.010), and ChP/ICV increased at 6-12 months (all q = 0.010).
DISCUSSION: The ALPS index and ChP volume may be insufficient as stand-alone surrogate endpoints over 12 months. These findings suggest exploring complementary strategies targeting CSF-ISF exchange and clearance pathways and warrant larger controlled longitudinal studies.
CLINICAL TRIAL REGISTRATION INFORMATION: Not applicable (observational study).